Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2003 2
2005 1
2006 1
2007 1
2009 4
2012 4
2013 1
2014 2
2015 2
2016 3
2018 2
2020 1
2024 0

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

23 results

Results by year

Filters applied: . Clear all
Page 1
HiSCR (Hidradenitis Suppurativa Clinical Response): a novel clinical endpoint to evaluate therapeutic outcomes in patients with hidradenitis suppurativa from the placebo-controlled portion of a phase 2 adalimumab study.
Kimball AB, Sobell JM, Zouboulis CC, Gu Y, Williams DA, Sundaram M, Teixeira HD, Jemec GB. Kimball AB, et al. Among authors: sobell jm. J Eur Acad Dermatol Venereol. 2016 Jun;30(6):989-94. doi: 10.1111/jdv.13216. Epub 2015 Jul 22. J Eur Acad Dermatol Venereol. 2016. PMID: 26201313 Free PMC article. Clinical Trial.
Introduction. Dermatitis.
Sikora BC, Sobell JM. Sikora BC, et al. Among authors: sobell jm. Semin Cutan Med Surg. 2013 Sep;32(3):131. doi: 10.12788/j.sder.0033. Semin Cutan Med Surg. 2013. PMID: 24175399 No abstract available.
Therapeutic development in psoriasis.
Sobell JM, Leonardi CL. Sobell JM, et al. Semin Cutan Med Surg. 2014 Jun;33(4 Suppl):S69-72. doi: 10.12788/j.sder.0098. Semin Cutan Med Surg. 2014. PMID: 25268599 Review.
Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials.
Griffiths CE, Reich K, Lebwohl M, van de Kerkhof P, Paul C, Menter A, Cameron GS, Erickson J, Zhang L, Secrest RJ, Ball S, Braun DK, Osuntokun OO, Heffernan MP, Nickoloff BJ, Papp K; UNCOVER-2 and UNCOVER-3 investigators. Griffiths CE, et al. Lancet. 2015 Aug 8;386(9993):541-51. doi: 10.1016/S0140-6736(15)60125-8. Epub 2015 Jun 10. Lancet. 2015. PMID: 26072109 Clinical Trial.
The role of TNF inhibitors in psoriatic disease.
Mandell BF, Sobell JM. Mandell BF, et al. Among authors: sobell jm. Semin Cutan Med Surg. 2014 Jun;33(4 Suppl):S64-8. doi: 10.12788/j.sder.0097. Semin Cutan Med Surg. 2014. PMID: 25268598 Review.
Update on TNF Inhibitors in Dermatology.
Sobell JM. Sobell JM. Semin Cutan Med Surg. 2016 Jun;35(6 Suppl):S104-6. doi: 10.12788/j.sder.2016.033. Semin Cutan Med Surg. 2016. PMID: 27537073
Defining drug-free remission of skin disease in patients with plaque psoriasis.
Armstrong AW, Blauvelt A, Crowley JJ, Gordon KB, Krueger GG, Krueger JG, Sobell JM, Strober BE, Srivastava B, Menter A. Armstrong AW, et al. Among authors: sobell jm. Br J Dermatol. 2020 Jun;182(6):1484-1487. doi: 10.1111/bjd.18694. Epub 2020 Jan 29. Br J Dermatol. 2020. PMID: 31705649 No abstract available.
23 results